Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer.
Neoadjuvant chemotherapy (NAC), the systematic chemotherapy given to patients with locally advanced and inoperable breast caner, has been proven to be of great clinical values. Many scientific reports confirmed NAC could effectively eliminate sub-clinical disseminated lesions of tumor, and improve long-term and disease-free survival rate of patients with locally advanced breast cancer (LABC); however, up to now, LABC is still a serious clinical issue given improved screening and early diagnosis. This study, with main focus on inoperable LABC, investigated the values of NAC in converting inoperable LABC into operable status and assessed the prognosis. Sixty-one patients with inoperable LABC were initially treated with neoadjuvant chemotherapy; their local conditions were improved to operable status. Radical surgery was exerted on 49 patients. Original chemotherapy was performed after surgery, followed by local radiotherapy. And endocrine therapy was optional according to the hormone receptor status. The quality of life for most patients with skin diabrosis was obviously improved because their local conditions were under control. For all recruited cases, the survival duration and life quality were significantly improved in patients who finished both NAC and surgery compared to those who did not. Further more, this study demonstrates improved prognostic consequences.
Center of Breast Disease, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China.
Minghao
M
Wang
Center of Breast Disease, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China.|Department of Thyroid Breast Surgery, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, China.
Lingmi
L
Hou
Department of Breast and Thyroid Surgery, Suining Central Hospital, #127 De-sheng Rd, Chuan-shan District, Suining, Sichuan province, 629000, China.
Maoshan
M
Chen
Center of Breast Disease, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China.
Yan
Y
Zhou
Center of Breast Disease, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China.
Yueyang
Y
Liang
Center of Breast Disease, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China.
Shushu
S
Wang
Center of Breast Disease, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China.
Jun
J
Jiang
Center of Breast Disease, Southwest Hospital, The Third Military Medical University, Chongqing, 400038, China.
Yi
Y
Zhang
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000071960:Breast Carcinoma In Situ / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005720:Gamma Rays / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D011379:Prognosis; D011788:Quality of Life; D016019:Survival Analysis